Correction: Melatonin attenuated the brain damage and cognitive impairment partially through MT2 melatonin receptor in mice with chronic cerebral hypoperfusion

Tzu-Hsien Tsai; Cheng-Jei Lin; Sarah Chua; Sheng-Ying Chung; Cheng-Hsu Yang; Meng-Shen Tong; Chi-Ling Hang

doi:10.18632/oncotarget.27754

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Melatonin attenuated the brain damage and cognitive impairment partially through MT2 melatonin receptor in mice with chronic cerebral hypoperfusion

PDF | How to cite

Oncotarget. 2020; 11:3558-3558. https://doi.org/10.18632/oncotarget.27754

Metrics: PDF 1040 views | ?

Tzu-Hsien Tsai^1,2, Cheng-Jei Lin¹, Sarah Chua¹, Sheng-Ying Chung¹, Cheng-Hsu Yang¹, Meng-Shen Tong¹ and Chi-Ling Hang¹

¹ Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
² Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Published: September 22, 2020

This article has been corrected: The co-first author, Cheng-Jei Lin, has been removed as an equal contributor for this study as compared to the first author.

Original article: Oncotarget. 2017; 8:74320–74330. DOI: https://doi.org/10.18632/oncotarget.20382.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27754

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Melatonin attenuated the brain damage and cognitive impairment partially through MT2 melatonin receptor in mice with chronic cerebral hypoperfusion